Richard T. Silver

A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha

Richard T. Silver, Hans Carl Hasselbalch

During the past 35 years, single-arm studies documented the efficacy and safety of recombinant interferon alpha (rIFNα) for treating polycythemia vera (PV). In some patients, 2-5 years of disease-modifying treatment resulted in symptom relief, regression of splenomegaly, normalization of abnormal blood counts …

us, dk (code pays fourni par la source)

Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera

Neville Lee, Katie Erdos, A Rahman, Richard T. Silver et autres

us, qa (code pays fourni par la source)

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Jane F. Apperley, Dragana Milojković, Nicholas C.P. Cross, Henrik Hjorth‐Hansen et autres

In this 5th version of the European LeukemiaNet guidance for adult patients, there are important changes in several areas of management based on evidence available since 2020, including the World Health Organisation's reclassification of CML as a biphasic disease. Previous advice to …

gb, no, de, us, ca, in, fr, it, se, ru, es, au, nl, cn, kr, cz (code pays fourni par la source)

1217 Cell-Depleted Stage Myelofibrosis: a Clinicopathologic Investigation of 135 Patients from the Bone Marrow Pathology Group

Julia T. Geyer, Ghaith Abu Zeinah, Daniel A. Arber, Adam Bagg et autres

us (code pays fourni par la source)

Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative Neoplasms

Spencer Krichevsky, Evan Sholle, Joseph M. Scandura, Prakash Adekkanattu et autres

Abstract Assessing treatment response in patients with myeloproliferative neoplasms is difficult because data components exist in unstructured bone marrow pathology (hematopathology) reports, which require specialized, manual annotation, and interpretation. Although natural language processing (NLP) has been successfully implemented for the extraction of …

us (code pays fourni par la source)

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Neville Lee, Katie Erdos, A Rahman, Richard T. Silver et autres

Background: Interferon alfa, in the form of ROPEG or PEG, is an effective first-line treatment (Rx) for patients (pts) with PV, associated with disease-modifying activity and favorable survival outcomes. ROPEG was approved by the FDA for PV in November 2021 but has …

us, qa (code pays fourni par la source)

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Bárbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi et autres

Background Over the past 15 years, the field of myelofibrosis (MF) has seen remarkable improvements in terms of risk stratification, with the development of clinical, clinico-genomic, as well as treatment-specific models. JAK inhibitors revolutionized the treatment of MF, while allogeneic hematopoietic cell …

de, it, es, us, fr, au, be (code pays fourni par la source)

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, Norio Komatsu et autres

Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms (MPNs) and patients require greater attention and likely require earlier therapeutic intervention. Progressive anemia, splenomegaly, and systemic symptoms accompanied by bone marrow myeloproliferation and fibrosis characterize the clinical burden of myelofibrosis …

us, hk, jp (code pays fourni par la source)

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)

Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, Marie Liu et autres

Despite the established potentially curative role of allogeneic hematopoietic cell transplantation (allo-HCT) in managing myelofibrosis (MF), the choice of alternative donors for patients lacking matched donors remains a challenge, and the optimal graft source in this disease entity continues to be an …

us (code pays fourni par la source)

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis

Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, Norio Komatsu et autres

Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms and patients require greater attention and likely require earlier therapeutic intervention. Currently approved treatment options are limited in their selective suppression of clonal proliferation resulting from driver- and coexisting gene mutations. …

us, hk, jp (code pays fourni par la source)

Are thrombosis, progression, and survival in ET predictable?

Ghaith Abu‐Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe et autres

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) that originates from a hematopoietic stem cell harboring a mutated JAK2 , CALR , or MPL gene, or none of these three mutations (10–15% are “triple negative”). Although considered the most indolent MPN, …

us, qa (code pays fourni par la source)

Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes

Reem S. Chamseddine, Oleksandr Savenkov, Shehroz Rana, Mohammed Khalid et autres

ABSTRACT: Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data support this approach. To support objective risk/benefit assessment of cytoreductive drugs in patients with …

qa, us (code pays fourni par la source)